Marcela V. Maus, M.d.,ph.d.

This early-stage trial is testing a new treatment called CARv3-TEAM-E T cells for people with glioblastoma, a serious brain cancer that has come back. The treatment uses a patient's own immune cells that are modified in a lab to better recognize and attack the cancer. The main go…

This early-phase trial is testing a new treatment called CC-97540, a type of CAR T cell therapy, in 12 people with severe ANCA-associated vasculitis that has not responded to standard treatments. The therapy is designed to target and destroy certain immune cells that drive the di…

This early-phase trial is testing a new type of CAR T cell therapy called TriPRIL for people with multiple myeloma that has returned or stopped responding to standard treatments. The therapy involves collecting a patient's own immune cells, modifying them to better attack cancer,…

This early-phase study tests a new type of immune cell therapy (CAR T cells) that targets two proteins, CD79b and CD19, on lymphoma cells. It is for people with non-Hodgkin lymphoma whose cancer has returned or stopped responding to standard treatments. The main goals are to chec…

This phase 2 trial tests whether emapalumab, a drug that blocks a protein called interferon gamma, can prevent severe cytokine release syndrome (CRS) in patients receiving CAR-T cell therapy for certain types of non-Hodgkin lymphoma. About 28 adults with relapsed or refractory la…

This study follows 45 adults who previously received CAR T cell therapy in earlier trials. Researchers will track their health for years using scans, blood tests, and physical exams to see how long the treatment's effects last and whether any late side effects appear. The goal is…